Ovarian cancer risk not affected by alcohol and smoking, but reduced b...(trongest for women who had never used or...),Health
Navigation Links
Ovarian cancer risk not affected by alcohol and smoking, but reduced by caffeine
Date:1/21/2008
trongest for women who had never used oral contraceptives or postmenopausal hormones.
The authors concluded that reducing alcohol intake and cessation of smoking is not likely to have a substantial impact on risk of ovarian cancer. They add that the possibility that caffeine may reduce ovarian cancer risk, particularly for women who have not previously used exogenous hormones, is intriguing and warrants further study, including an evaluation of possible biological mechanisms.
'/>"/>
| Contact: Amy Molnar amolnar@wiley.com Wiley-Blackwell Source:Eurekalert |
Related medicine news :
1. Cranberry Could Juice Up Ovarian Cancer Treatment
2. New Ovarian Cancer Drug Trial Under Way
3. Pelvic Exams Can Help Spot Ovarian Cancer
4. Study fuels debate over whether exercise and body size influence ovarian cancer risk
5. Experimental drug boosts survival in recurrent ovarian cancer
6. New Ovarian Cancer Biomarker Research Act Introduced
7. Common Early-Warning Symptoms of Ovarian Cancer Identified in CDC/Thomson Healthcare Study
8. More Fiber, Less Fat Help Prevent Ovarian Cancer
9. Media availability: low-fat dietary pattern may lower risk of ovarian cancer
10. The Silent Killer, Ovarian Cancer on Your Cancer Today (TM)
11. Society of Gynecologic Oncologists Provides Guidelines for Offering Genetic Risk Assessment to Women With a Personal or Family History of Breast, Ovarian, Uterine or Colorectal Cancer
Post Your Comments:
(Date:1/8/2009)...ewswire/ -- The Pew Charitable Trusts announced to...emical and food safety programs, in its Health &am...ormerly deputy staff director and general counsel ...Works, brings nearly 25 years of experience in env..., , "We are excited to be joined by such an expe...
(Date:1/8/2009)...rstCall/ -- Cephalon, Inc . (Nasdaq: CEPH ) tod...man and CEO will present at the J.P. Morgan Healt...n San Francisco, CA at approximately 4:00 p.m. Pac...will be webcast live on the investor relations sec... will be archived for one week following the broad...
(Date:1/8/2009)...e-FirstCall/ -- Heska Corporation (Nasdaq: HSKA ...hat: Heska Corporation Invites You to Join Its...arnings Conference Call on the Web, When: ...Where: www.heska.com (click on the Q4 and Year-...front page of this website)., How: Live...
(Date:1/8/2009)...wire/ -- St. Jude Children,s Research,Hospital(R)...Cup Runner-Up,Camilo Villegas has increased his c... match Singh,s donation of $5,000 to St. Jude for ...s for St. Jude is a powerful program that,has uni...sing LPGA star Morgan,Pressel, along with the Gol...
Breaking Medicine News(10 mins):Health News:Veteran Environmental Health Expert Erik D. Olson to Join Pew 2Health News:Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference 2Health News:Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference 3Health News:Webcast Alert: Heska Announces Fourth Quarter and Year-End 2008 Earnings Conference Call Webcast 2Health News:Not to be Outdone by FedExCup Champion Vijay Singh, FedExCup Runner-Up Camilo Villegas Increases Commitment to Children of St. Jude 2Health News:Not to be Outdone by FedExCup Champion Vijay Singh, FedExCup Runner-Up Camilo Villegas Increases Commitment to Children of St. Jude 3Health News:Not to be Outdone by FedExCup Champion Vijay Singh, FedExCup Runner-Up Camilo Villegas Increases Commitment to Children of St. Jude 4[0] Veteran Environmental Health Expert Erik D. Olson to Join Pew[0] Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference[0] Webcast Alert: Heska Announces Fourth Quarter and Year-End 2008 Earnings Conference Call Webcast[0] Not to be Outdone by FedExCup Champion Vijay Singh, FedExCup Runner-Up Camilo Villegas Increases Commitment to Children of St. Jude
...o latest research , sudden emotional stress can re...s that mimics a classic heart attack.// Stress ca...sive heart attack. According to the researchers, p...rge in adrenalin and other stress hormones that te...
...ndings of a recent study researchers say , cancer ...us thrombosis, // or blood clots in the legs or lu...o 70, who had a blood clot in their legs or lungs....he presence of distant metastases, and carrier sta...
...world congress for diabetes begins in Chennai toda...betes and its complications //and over 1000 doctor...untries across the world. The world congress for...very three years, since the time of its inception ...
...tion therapy is used to treat deep vein thrombosis...is or arms. Researchers say several new studies sh...plify anticoagulation therapy.// In the first stu...hrombosis) patients and compared the effectiveness...
Other Medicine News:(Date:1/8/2009)... initial dose in an ongoing Phase Ib trial demonst...three days , , Conference Call Today at 8:30AM ...l/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS...f an ongoing Phase Ib clinical trial of ANA598, th...ase inhibitor. ANA598 was very well-tolerated and...
(Date:1/7/2009)...ts in Development Based On Osteotech,s Proprietary...oRegeneration; FDA Filing Anticipated in Third Qua...ire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OST...oducts for regenerative healing, announced today t...its DuraTech(TM) BioRegeneration Matrix. The first...
(Date:1/6/2009)...PRNewswire/ -- In recent controlled studies conduc... , scientists found that the patented ingredient i...ly proven ingredient to increase levels of nitric ...itrate/nitrate (NOx) in human subjects. , , Nit...rease in blood flow to the skeletal muscles. This...
(Date:1/6/2009)...ary 6 , - Early R...n Until,December 2011 , - Expansion of the...iscovery in Ophthalmology , - Revised Comme...ublicenses to a Third Party , ExonHit The...nforcement,of its existing drug discovery collabo...
Breaking Medicine Technology:ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 2ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 3ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 4ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 5ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 6Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix 2Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix 3US Testing Proves Glyc'n Go(TM) Increases NO in the Blood Stream 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 3ExonHit Therapeutics Expands Strategic Collaboration With Allergan 4Nexia Closes Acquisition of Green Endeavors 3B Landis Salons On Track to Generate Revenues of 242 2 Million in 2007 4148 1Nexia Closes Acquisition of Green Endeavors 3B Landis Salons On Track to Generate Revenues of 242 2 Million in 2007 4148 2Nexia Closes Acquisition of Green Endeavors 3B Landis Salons On Track to Generate Revenues of 242 2 Million in 2007 4148 3Nexia Closes Acquisition of Green Endeavors 3B Landis Salons On Track to Generate Revenues of 242 2 Million in 2007 4148 4Maxygen Third Quarter 2007 Financial Results Conference Call Notice 1375 1Maxygen Third Quarter 2007 Financial Results Conference Call Notice 1375 2AQUISS Continues Expansion Into New Territory 1372 1AQUISS Continues Expansion Into New Territory 1372 2Key found to moonlight romance 889 1Key found to moonlight romance 889 2Key found to moonlight romance 889 3[0] ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients[0] Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix[0] US Testing Proves Glyc'n Go(TM) Increases NO in the Blood Stream[2] ExonHit Therapeutics Expands Strategic Collaboration With Allergan
...ICAGO and REGENSBURG - June 21, 2007 - “In a...s actually clearly superior,to temozolomide,&rdquo...lifornia, U.S.A. commented on the international Ph...09, under development,by Antisense Pharma. Prof. W...er discussion session on central nervous system tu...
...ICAGO, June 21, 2007 /PRNewswire/ -- , What and Wh...f ACTOS(R),(pioglitazone HCl) will be presented in...the American Diabetes Association in,Chicago: , , ...in high-risk type 2, diabetes patients trea... PROactive; Poster 0553-P presented on Saturd...
Other Medicine Technology:Antisense Pharma: Promising Phase IIb Results of Targeted Therapy,with AP 12009 in Recurrent Anaplastic Astrocytoma 2Antisense Pharma: Promising Phase IIb Results of Targeted Therapy,with AP 12009 in Recurrent Anaplastic Astrocytoma 3Antisense Pharma: Promising Phase IIb Results of Targeted Therapy,with AP 12009 in Recurrent Anaplastic Astrocytoma 4MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating,MacroVascular Outcomes Presented at the American Diabetes,Association 67th Scientific Sessions 2MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating,MacroVascular Outcomes Presented at the American Diabetes,Association 67th Scientific Sessions 3...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
Medicine Products:| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |